Jason Zemansky
Stock Analyst at B of A Securities
(4.78)
# 62
Out of 5,182 analysts
55
Total ratings
69.23%
Success rate
39.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $8 → $9 | $3.55 | +153.52% | 6 | Mar 30, 2026 | |
| INSM Insmed | Maintains: Buy | $211 → $213 | $162.43 | +31.13% | 12 | Mar 24, 2026 | |
| LGND Ligand Pharmaceuticals | Initiates: Buy | $244 | $199.59 | +22.25% | 1 | Mar 11, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Buy | $34 | $9.90 | +243.43% | 1 | Mar 2, 2026 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $6 | $1.80 | +233.33% | 1 | Jan 21, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $18 → $19 | $12.00 | +58.33% | 3 | Nov 28, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $17 → $26 | $22.96 | +13.24% | 6 | Nov 28, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $8 → $7 | $1.01 | +593.07% | 6 | Nov 18, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $52 → $56 | $66.73 | -16.08% | 5 | Oct 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $30.44 | +1.84% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $29 | $8.61 | +236.82% | 2 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $31 | $25.15 | +23.26% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $2.9 → $2.5 | $2.61 | -4.21% | 5 | Jun 20, 2024 |
Rocket Pharmaceuticals
Mar 30, 2026
Maintains: Buy
Price Target: $8 → $9
Current: $3.55
Upside: +153.52%
Insmed
Mar 24, 2026
Maintains: Buy
Price Target: $211 → $213
Current: $162.43
Upside: +31.13%
Ligand Pharmaceuticals
Mar 11, 2026
Initiates: Buy
Price Target: $244
Current: $199.59
Upside: +22.25%
Eikon Therapeutics
Mar 2, 2026
Initiates: Buy
Price Target: $34
Current: $9.90
Upside: +243.43%
Inhibikase Therapeutics
Jan 21, 2026
Initiates: Buy
Price Target: $6
Current: $1.80
Upside: +233.33%
Keros Therapeutics
Nov 28, 2025
Maintains: Neutral
Price Target: $18 → $19
Current: $12.00
Upside: +58.33%
Arcus Biosciences
Nov 28, 2025
Maintains: Neutral
Price Target: $17 → $26
Current: $22.96
Upside: +13.24%
Werewolf Therapeutics
Nov 18, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $1.01
Upside: +593.07%
Cytokinetics
Oct 2, 2025
Maintains: Neutral
Price Target: $52 → $56
Current: $66.73
Upside: -16.08%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $30.44
Upside: +1.84%
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $8.61
Upside: +236.82%
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $25.15
Upside: +23.26%
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $2.61
Upside: -4.21%